$PSNL News

Morgan Stanley Maintains Equal-Weight on Personalis, Raises Price Target to $13

Personalis Enables Global Biopharma Support with CE-IVD Marked Specimen Collection Kits

Personalis Wins EU Compliance Mark for Cancer Testing Blood Kits, Blood Collection Kits Receive European Diagnostic Mark

Personalis CEO Sells 100,000 Company Shares Worth $1.1 Million. What Does That Mean for Investors?

Personalis Highlights Early Colorectal Cancer Recurrence Detection and Ultrasensitive MRD Performance Across a Broad Set of Tumor Types at ASCO 2026

Personalis Highlights Cancer-Detection Data Across Multiple Tumor Types

Assessing Personalis (PSNL) Valuation After Its Strong Recent Share Price Momentum

Personalis: Initiating Coverage Of Cancer Testing Biotech With A Buy Rating

Personalis to Highlight Breadth of NeXT Personal® Ultra-Sensitive ctDNA Data at ASCO 2026 Annual Meeting, Including Podium Presentation from TRACERx Consortium

Personalis to Present New Cancer Detection Data at Major Oncology Conference

US Agency Broadens Coverage Of Personalis Breast Cancer Test

Personalis Secures Fourth Medicare Coverage Decision for NeXT Personal®, Expanding Breast Cancer Coverage to Pre-Surgical Treatment Monitoring

Personalis to Participate in Upcoming Investor Events

Personalis Receives Medicare Coverage for NeXT Personal® for Immunotherapy Monitoring Across Late-stage Solid Tumors

Morgan Stanley Maintains Equal-Weight on Personalis, Lowers Price Target to $9

BTIG Maintains Buy on Personalis, Lowers Price Target to $11

Personalis Q1 Earnings Call Highlights

Personalis, Inc. (PSNL) Q1 2026 Earnings Call Transcript

Personalis (PSNL) Q1 2026 Earnings Transcript

Personalis, Inc. Q1 2026 Earnings Call Summary